维普期刊资源整合服务平台（V6.5）

28篇 您的检索式：作者名="Ottmann O"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Response toimatinib in patients who relapse after allogeneic stem celltransplantation for chronic myeloid leukemia 显示文摘	Olavarria E Ottmann O G Deininger M	2003	Leukemia2003，17，9：	1
2	Acute lymphoblastic leukemia显示文摘	Hoelzer D Gkbuget N Ottmann O Pui CH Relling MV Appelbaum FR	2002	Hematology Am Soc Hematol Educ Program2002，，：	1
3	Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) 显示文摘	Ottmann O G Wassmann B Pfeifer H	2007	Cancer2007，109，10：	1
4	phase II study of nilotinlb in patients with relapsed or refractory Philadelphia chromosome positive acute lymphoid leukemias 显示文摘	OTTMANN O G LARSON R A KANTARJIAN H M	2013	Leukemia2013，27，6：	1
5	Constitutive NF-kappab/Rel activation in Philadelphia chromosome positive(Ph +)acute lymphoblastic leukemia(ALL)显示文摘	Munzert G Kirchner D Ottmann O	2004	Leuk Lymphoma2004，45，6：	1
6	Mechanisms of Bcr-Abl-mediated NFkappaB/Rel activation显示文摘	Kirchner D Duyster J Ottmann O	2003	Exp Hematol2003，31，6：	1
7	Mechanisms of Bcr- Abl-mediated NF-kappaB / Rel activation 显示文摘	Kirchner D Duyster J Ottmann O	2003	Exp Hematol2003，31，6：	1
8	Acute lympho- blastic leukemia 显示文摘	Hoelzer D GSkbuget N Ottmann O	2002	Hematology Am Soc Hematol Educ Program2002，，：	1
9	Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib:interim results of a phase 2study显示文摘	Ottmann O Dombret H Martinelli G	2007	Blood2007，110，：	1
10	Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation 显示文摘	Kirchner D Duyster J Ottmann O	2003	Exp Hematol2003，31，6：	1
11	Treatment of Philadelphia chromosome positive acute lymphoblastic leukemia显示文摘	Ottmann O G Wassmann B	2005	Hematology2005，，：	1
12	Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels 显示文摘	HOFMANN W K SEIPELT G OTTMANN O G	2000	Ann Hematol2000，79，：	1
13	FLT3-ITD-, but not BCR/ABL-transfonned cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment显示文摘	CAID WANG Y OTTMANN O G	2006	Blood2006，107，5：	1
14	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia显示文摘	LE COUTRE P OTTMANN O G GILES F	2008	Blood2008，111，：	1
15	Phase IA/Ⅱ study of oral panobinostat (LBH589),a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies显示文摘	Ottmann O G Spencer A Prince H M	2008	Blood2008，112，：	1
16	Acute lymphoblastic leukemia显示文摘	Hoelaze D Gokbuget N Ottmann O	2002	Hematology(Am Soc Hematol Educ Progarrn)2002，，1：	1
17	A phase Ⅱ study of imatinib Mesylate (Gleevec) in patients with relapsed or refractory Philadelphia chromosome positive acute lymphoid leukemia 显示文摘	Ottmann O G Druker B J Sawyers C L	2002	Blood2002，100，：	1
18	Chromo- somal organization and localization of the human histone deacetylase 5 gene(HDAC5)显示文摘	Mahlknecht U Schnittger S Ottmann O G	2000	Biochim Biophys Acta2000，1493，3：	1
19	Nilotinib (formerly AMN107), a highly selective BCR ABL tyrosine kinase inhibitor, is active in patients with imatinih-resistant or-intolerant accelerated-phase chronicmyelogenous leukemi显示文摘	LE COUTRE P OTTMANN O G GILES F	2008	Blood2008，111，：	1
20	Nilotinib formerly AMN107,a highly selective BCR-ABL tyrosine kinase inhibitor,is activein patients with imatinib resistant or intolerant accelerated-phasechronic myelogenous leukemia显示文摘	Le Coutre P Ottmann O G Giles F	2008	Blood2008，1114，1：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示